Research Paper Volume 12, Issue 4 pp 3848—3861
Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation
Figure 5. H&E staining and IHC analysis of different treatment groups. Results of H&E staining and IHC analysis in the different treatment groups in the (A) D17225 and (B) B45354 PDX model. (C) Representative images of liver metastasis and the parental tumors after treatment with docetaxel in the B45354 PDX model. (D) Expression of neuroendocrine carcinoma markers SYP and CGA after treatment with castration + docetaxel in the B45354 PDX model.